Anti-aldehyde dehydrogenase therapeutic strategies are planned in different preclinical settings [41, 42], whereas our present study suggests that such drugs might exert adverse effects if the tumor contains ALDH1(+) stromal cells. The gene discussed is ALDH1A1; the disease is neoplasm.